These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251 [TBL] [Abstract][Full Text] [Related]
26. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Szinnai G; Meier C; Komminoth P; Zumsteg UW Pediatrics; 2003 Feb; 111(2):E132-9. PubMed ID: 12563086 [TBL] [Abstract][Full Text] [Related]
27. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290 [TBL] [Abstract][Full Text] [Related]
28. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880 [TBL] [Abstract][Full Text] [Related]
29. Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study. Twito O; Grozinsky-Glasberg S; Levy S; Bachar G; Gross DJ; Benbassat C; Rozental A; Hirsch D Eur J Endocrinol; 2019 Jul; 181(1):13-21. PubMed ID: 31048559 [TBL] [Abstract][Full Text] [Related]
30. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651 [TBL] [Abstract][Full Text] [Related]
31. Current surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET]. Czarniecka A; Oczko-Wojciechowska M; Hajduk A; Zeman M; Jarzab B Endokrynol Pol; 2019; 70(4):367-379. PubMed ID: 31489961 [TBL] [Abstract][Full Text] [Related]
32. Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation. Machens A; Lorenz K; Weber F; Dralle H Eur J Surg Oncol; 2021 Apr; 47(4):920-923. PubMed ID: 32962888 [TBL] [Abstract][Full Text] [Related]
33. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience. Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924 [TBL] [Abstract][Full Text] [Related]
34. Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES). Niederle B; Sebag F; Brauckhoff M Langenbecks Arch Surg; 2014 Feb; 399(2):185-97. PubMed ID: 24297502 [TBL] [Abstract][Full Text] [Related]
35. Current understanding and management of medullary thyroid cancer. Roy M; Chen H; Sippel RS Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980 [TBL] [Abstract][Full Text] [Related]
36. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related]
37. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905 [TBL] [Abstract][Full Text] [Related]
38. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma. Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163 [TBL] [Abstract][Full Text] [Related]
39. Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Essig GF; Porter K; Schneider D; Debora A; Lindsey SC; Busonero G; Fineberg D; Fruci B; Boelaert K; Smit JW; Meijer JA; Duntas L; Sharma N; Costante G; Filetti S; Sippel RS; Biondi B; Topliss DJ; Pacini F; Maciel RM; Walz PC; Kloos RT Endocr Pract; 2013; 19(6):920-7. PubMed ID: 23757627 [TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Modigliani E; Cohen R; Campos JM; Conte-Devolx B; Maes B; Boneu A; Schlumberger M; Bigorgne JC; Dumontier P; Leclerc L; Corcuff B; Guilhem I Clin Endocrinol (Oxf); 1998 Mar; 48(3):265-73. PubMed ID: 9578814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]